article thumbnail

The Pharmacy Benefit Management Landscape: A Music Industry Analogy

Drug Patent Watch

"The Prescription for Change: How PBM's are Ripping the Rhythm of the Pharmaceutical Industry Imagine a music industry where a single middleman controlled access to every song, dictating who could play them, when, and at what price. That's essentially the world of Pharmacy Benefit Managers (PBMs) in the pharmaceutical industry.

article thumbnail

Employers foresee higher health costs next year due to rising pharmacy spend

BioPharma Drive: Drug Pricing

Pharmaceuticals like the in-demand GLP-1 drugs for obesity are expected to drive increases in healthcare spending in 2025, per a new employer survey.

Pharmacy 277
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novel Pharmaceutical Strategies and Business Models: The Rise of Telehealth Companies Like Ro and Hims & Hers

Drug Patent Watch

"The Telehealth Revolution: How D2C Pharmacies Are Redefining the Industry In a seismic shift, direct-to-consumer (D2C) pharmacies like Ro, Hims, and Hers are upending traditional healthcare business models, leveraging telehealth to deliver convenient, affordable, and personalized care to millions. Read more: [link] "

article thumbnail

India’s Growing Importance in Generic Drug API Manufacturing

Drug Patent Watch

India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. The country’s pharmaceutical sector has experienced substantial growth over the years, driven by both domestic and international demand for affordable and high-quality medicines.

article thumbnail

Smaller Pharmacies, Bigger Impact: Inside Manufacturers’ Specialty Networks in 2025

Drug Channels

Last week, we examined the growing concentration of specialty drug dispensing revenues among the largest pharmacies. See The Top 15 Specialty Pharmacies of 2024: How PBMs, Health Systems, and Independents Are Shaping the Market. Today, we dive deeper. Drawing from DCIs new 2025 Economic Report on U.S.

article thumbnail

NOW AVAILABLE: The 2022 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Drug Channels

Pharmacies and Pharmacy Benefit Managers , available for purchase and immediate download. Pharmacies and Pharmacy Benefit Managers , our 13th edition, provides a comprehensive, fact-based, and non-partisan tool for understanding the entire U.S. I am pleased to announce our new 2022 Economic Report on U.S.

article thumbnail

Understanding CVS Health/McKesson and Why Pharmacies Lose Money on GLP-1s (rerun)

Drug Channels

Consider two apparently unrelated drug channel anomalies: In McKesson’s 2023 fiscal year, CVS bought $75 billion in pharmaceuticals from McKesson’s wholesale business—a jump of more than 35% compared with the previous year. Despite skyrocketing sales for anti-obesity GLP-1 drugs, many retail pharmacies are losing money on every prescription.